Meibomian Gland Dysfunction
Conditions
Keywords
Lipiflow, Meibomian gland dysfunction, Biometry
Brief summary
Accurate biometry is an essential and indispensable tool in preoperative cataract surgery setting to yield optimal postoperative refractive outcome. However, some recent studies indicate that preoperative biometry is influenced by dry eye disease (DED). Hence, the investigator's study aims to investigate the effect of the therapy of MGD using the Lipiflow® device on the stability of biometry and selection of IOL.
Detailed description
Accurate biometry is an essential and indispensable tool in preoperative cataract surgery setting to yield optimal postoperative refractive outcome. 31 Patients suffering from DED caused by MGD will be selected and allocated randomly to therapy. Patients with pre-existing DED therapy other than lubricants will be excluded. After completing prestudy-screening and baseline visit, Lipiflow® therapy is applied to the study eye. Follow-up visits will be scheduled two weeks and three months after baseline visit. Each visit includes dry eye investigations and IOL calculation by IOLmaster 700 and CSO MS-39. After each study visit an IOL will be theoretically selected.
Interventions
DEVICELipiflow treatment
Patients will be treated on one eye with Lipiflow
Sponsors
Vienna Institute for Research in Ocular Surgery
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
21 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* Age older than 18 years * Evidence of meibomian gland dysfunction * Meibomian gland secretion score equal or less than 15 (for 15 glands of the lower eye lid) using the meibomian gland evaluator (see below)
Exclusion criteria
* Usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-A) * Usage of systemic antibiotic therapy * Any pathology of the ocular surface except dry eye disease (e.g. corneal scarring, cornea ectasia) * Ocular surgery within prior 3 months * Ocular injury within prior 3 months * Ocular herpes of eye or eyelid within prior 3 months * Active ocular infection * Active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months * Eyelid abnormalities that affect lid function * Ocular surface abnormality that may compromise corneal integrity * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Spherical and toric IOL power selected at baseline and at 3 months visit | 12 months | The difference between pre- and post-treatment biometrical calculated IOL power will be calculated and compared |
Countries
Austria
Contacts
Primary ContactOliver Findl, Univ.Prof. Dr.
Backup ContactStefan Palkovits, Priv.Doz. Dr.
Outcome results
None listed